Stocks and Investing
Stocks and Investing
Mon, February 22, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Tejas Savant Maintained (TXG) at Buy with Increased Target to $215 on, Feb 22nd, 2021
Tejas Savant of Morgan Stanley, Maintained "10x Genomics, Inc." (TXG) at Buy with Increased Target from $145 to $215 on, Feb 22nd, 2021.
Tejas has made no other calls on TXG in the last 4 months.
There are 4 other peers that have a rating on TXG. Out of the 4 peers that are also analyzing TXG, 1 agrees with Tejas's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Amit Hazan of "Goldman Sachs" Initiated at Hold and Held Target at $150 on, Wednesday, December 2nd, 2020
These are the ratings of the 3 analyists that currently disagree with Tejas
- Doug Schenkel of "Cowen & Co." Maintained at Buy with Increased Target to $200 on, Thursday, February 18th, 2021
- Patrick Donnelly of "Citigroup" Maintained at Strong Buy with Increased Target to $240 on, Thursday, February 18th, 2021
- Tycho Peterson of "JP Morgan" Maintained at Buy with Increased Target to $195 on, Thursday, February 18th, 2021
Contributing Sources